These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2781538)

  • 1. An eight year experience with gradually longer interval postremission therapy for adults with acute leukemia.
    Kawamura S; Mikami T; Sawada Y; Chiba Y; Yoshida Y
    Tohoku J Exp Med; 1989 May; 158(1):17-24. PubMed ID: 2781538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An intensification therapy of adults acute leukemia].
    Kawamura S; Kawarada R; Tsushima Y; Sawada Y; Yoshida Y; Chiba Y; Yamaya T; Kawatsu S; Aizawa M; Segawa M
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):83-7. PubMed ID: 2643396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study.
    Ogata K; An E; Kamikubo K; Yokose N; Tamura H; Yamada T; Gomi S; Dan K; Nomura T
    Stem Cells; 1998; 16(4):280-7. PubMed ID: 9708450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative evaluation of combined chemotherapeutic regimens in acute non-lymphocytic leukemia].
    Sasaki H; Maekawa I; Kawamura S; Miyake T
    Hokkaido Igaku Zasshi; 1983 May; 58(3):271-8. PubMed ID: 6194091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The curative treatment of adult acute nonlymphocytic leukemia].
    Uzuka Y; Saito Y
    Rinsho Ketsueki; 1989 Aug; 30(8):1163-6. PubMed ID: 2601025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
    Yokose N; Ogata K; Ito T; Miyake K; An E; Inokuchi K; Yamada T; Gomi S; Tanabe Y; Ohki I
    Ann Hematol; 1993 Feb; 66(2):67-70. PubMed ID: 8383541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
    Yoshida M; Suda K; Tsuboyama A; Sasaki R; Kitagawa S; Kano Y; Muto Y; Takaku F; Sakamoto S; Miura Y
    Eur J Haematol; 1989 Jul; 43(1):1-6. PubMed ID: 2767238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
    Ohno R; Kato Y; Nagura E; Murase T; Okumura M; Yamada H; Ogura M; Minami S; Suzuki H; Morishima Y
    J Clin Oncol; 1986 Dec; 4(12):1740-7. PubMed ID: 3465875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
    Sampi K; Sakurai M; Kaneko Y; Hattori M
    Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
    Nagura E; Kimura K; Yamada K; Ohta K; Maekawa T; Takaku F; Uchino H; Masaoka T; Amaki I; Kawashima K
    Cancer Chemother Pharmacol; 1994; 34(1):23-9. PubMed ID: 8174198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer curable by chemotherapy: acute myelogenous leukemia].
    Ohno R; Tanimoto M; Morishita Y; Morishima Y; Saito H; Yokomaku S; Nagai T; Kodera Y; Minami S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
    Fujisawa S; Maruta A; Motomura S; Fukawa H; Kanamori H; Ogawa K; Matsuzaki M; Miyashita H; Harano H; Murata T; Sakai R; Mohri H; Kodama F; Okubo T
    Leuk Lymphoma; 1998 Mar; 29(1-2):161-70. PubMed ID: 9638985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.